S. Topalian
Oncology · 2002–2023
A researcher in the Science corpus: 27 papers; trusts 8 researchers and is trusted by 14 researchers here, as inferred from the citation graph.
Subfields
- Oncology — 306 citations into it; #176 of 1,698 by trust here, #15 by citations
- Immunology — 286 citations into it; #345 of 2,160 by trust here, #29 by citations
Whom S. Topalian trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
- Daniel L. Barber
- Taku Okazaki
- Janis Taube
- J. Wolchok
- D. Pardoll
- G. Freeman
- C. Robert
- Loise M. Francisco
- M. Keir
- M. Butte
Who trusts S. Topalian overall
- M. Postow
- A. Schietinger
- Daniel S. Chen
- Kristen E. Pauken
- Padmanee Sharma
- J. Wolchok
- Anna Katharina Simon
- Antoni Ribas
- W. Zou
- S. Wei
Papers from S. Topalian's perspective
Ordered by how strongly the researchers S. Topalian trusts endorse each paper. Same corpus, a different order for every researcher.
- Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. (Science)
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma (New England Journal of Medicine)
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer (New England Journal of Medicine)
- Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome (Science)
- Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma (Nature Medicine)
- Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity (Nature Medicine)
- The blockade of immune checkpoints in cancer immunotherapy (Nature Reviews. Cancer)
- PD-L2 is a second ligand for PD-1 and inhibits T cell activation (Nature Immunology)
- The B7 family revisited. (Annual Review of Immunology)
- Restoring function in exhausted CD8 T cells during chronic viral infection (Nature)
Their papers
- A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. (2003) — 2,835 citations
- Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. (2005) — 987 citations
- Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. (2017) — 985 citations
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab (2023) — 1,526 citations
- Neoadjuvant checkpoint blockade for cancer immunotherapy (2020) — 879 citations
- Neoadjuvant PD-1 Blockade in Resectable Lung Cancer (2018) — 1,781 citations
- PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. (2016) — 1,115 citations
- Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy (2016) — 2,482 citations
- Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. (2015) — 1,081 citations
- Immune checkpoint blockade: a common denominator approach to cancer therapy (2015) — 3,868 citations
- Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy (2014) — 2,243 citations
- Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma (2013) — 738 citations
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer (2012) — 11,924 citations
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape (2012) — 2,143 citations
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer (2012) — 7,418 citations
- Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity (2012) — 1,310 citations
- Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1. (2011) — 1,473 citations
- Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma (2010) — 1,107 citations
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates (2010) — 2,866 citations
- Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and Hypophysitis (2007) — 703 citations